MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director

Rhea-AI Summary

MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT) appoints Maher Masoud as President and CEO, effective January 1, 2024, and discloses his stock options. The company focuses on cell-engineering technologies for cell therapeutics and bioprocessing applications.

ROCKVILLE, Md., Jan. 01, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, is pleased to confirm the appointment of Maher Masoud as President and Chief Executive Officer of MaxCyte effective as of January 1, 2024. In addition, Mr. Masoud now serves as a director on MaxCyte’s Board of Directors.

Regulatory

Pursuant to Rule 17 of the AIM Rules for Companies ("AIM Rules") and Schedule Two Paragraph (g) of the AIM Rules, Mr. Maher Issa Masoud, aged 48 does not currently have any other directorship or partnership appointments and has not been a director or a partner of another company within the previous five years. Mr. Masoud also holds 674,200 options over common stock of the Company. There is no further information which is required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies in respect of Mr. Masoud.

MaxCyte Contacts:

US IR Adviser  Gilmartin Group  David Deuchler, CFA	+1 415-937-5400  ir@maxcyte.com
US Media Relations Seismic Valerie Enes	+1 408-497-8568
Nominated Adviser and Joint Corporate Broker  Panmure Gordon  Emma Earl / Freddy Crossley  Corporate Broking  Rupert Dearden	+44 (0)20 7886 2500
UK IR Adviser ICR Consilium Mary-Jane Elliott Chris Welsh	+44 (0)203 709 5700 maxcyte@consilium-comms.com

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation^® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical, and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on Twitter and LinkedIn.

FAQ

Who is the new President and CEO of MaxCyte, Inc.?

Maher Masoud has been appointed as the new President and Chief Executive Officer of MaxCyte, Inc., effective as of January 1, 2024.

What is MaxCyte, Inc.'s ticker symbol?

The ticker symbols for MaxCyte, Inc. are NASDAQ: MXCT and LSE: MXCT.

What does MaxCyte, Inc. focus on?

MaxCyte, Inc. is a cell-engineering focused company providing enabling platform technologies for next-generation cell therapeutics and innovative bioprocessing applications.

What are the contact details for MaxCyte, Inc.'s US IR Adviser?

The US IR Adviser for MaxCyte, Inc. is Gilmartin Group. Contact David Deuchler, CFA at +1 415-937-5400 or ir@maxcyte.com.

What are the contact details for MaxCyte, Inc.'s US Media Relations?

For US Media Relations, contact Seismic at +1 408-497-8568.